Oof. What a day. My first thought, and something I

New Post Public Reply Private Reply Replies (1) Message Board
Respert24
893
Oof.

What a day.

My first thought, and something I fired off immediately to a fellow board member via email this morning, was “Wow, a press release at 9:26am where we hit a primary endpoint! But why no mention of 700mg? And why was their no mention of the BTD that Nader has thrown out multiple times as imminent once we get good results?”

Their response?

Samesies.

But here’s the thing. We all should know by now that we aren’t getting results quickly from these trials. There’s this unrealistic belief that once results are unblinded we should know within hours. While there’s some truth in the theory that they should be able to count deaths and do some quick math for a primary endpoint, there is far more that goes into compiling and presenting these results. It’s always slow and this PR was a good example. Nader said he believed we’d be hitting our primary and secondary endpoints of the 350mg arm a week and a half or so before Christmas. Then we were told we’d get results by Christmas. That second part didn’t happen, obviously. But think about how long it took and then consider we were just then getting the 700mg data for the first time soon after. It’s only been a couple weeks and we had two major holidays smushed in there. Be patient. There’s no reason to assume the results would be bad. By all accounts, the 700mg group should do equal to, or better than, the 350mg group.

I also was invested in 2019, which was a year where every time a good PR came about we’d be down the first day and then up the day or two after. There’s an old Emo Phillips joke about joke grenades, if I’m remembering who came up with the joke correctly. That’s how I always felt about the PR’s back in the year of our lord and savior, 2019. They always took extra time to land.

Some say this PR was a smokescreen for a bad BTD outcome. I highly doubt this is the case. We may not get the designation approved by the FDA, but since when does Nader get strategic with PR’s? Outside of trying to throw exciting “mights” and “maybes” in there, he’s definitely not playing three dimensional chess with his pressers. He’s dropped solid PR’s on the weekend, at 7pm eastern time, at 2am eastern time, and a variety of other inconsistent and not at all strategic times of the day.

Some wonder if the comment about biomarkers is because the 700mg results are bad and they’re hoping to glean some sort of positive information from the trial using those markers. To that I declare Shenanigans. You may as well call him ERecktnor for how excited he gets about biomarker data. He is heavily focused on biomarkers regardless of trial, so this isn’t some sort of feint to draw us away from some bad results. It’s him being him. They track this shit and it’s important. The more we know about exactly who this baby works on, and exactly why it’s working, the stronger our trials will be and the easier our approvals will be.

Please don’t short your brains, this isn’t all some constant game of strategery between Nader and the world. And Nader or the fair market are not the sole reasons we’ve had the run up to $10 and the fall back under a buck. Those are simple explanations for a much more complex answer. They’re both a part of things, but there’s so much more.

Some have said that with the volume we had today (around 7 million shares) this can’t be all shorts. But I’d ask you how then, did we see eight separate million share sell orders on the day we dropped hard from $10? Seven million shares at a buck or less would be easy if one were dead set on fuckery.

#Fuckery

Some people wonder if this or that is priced in. Hey guess what, we barely have a price right now at under a dollar. I think the only things priced in are the cost of the coffee mugs and extra microwaves because once you cook fish in a break room microwave a few times they’re never the same again. I pity the fool who thinks he can reheat some pasta after NP has blown up the ‘wave with yet another salmon cooked from raw.

Some say, “But Respert, you have your good looks and rapist’s wit to fall back on if this investment goes sideways. Not all of us are that fortunate.” And they wouldn’t be wrong. We all come at this investment opportunity with different circumstances and some of you are straight uggos. It’s science and statistics, don’t get mad at me. If anything, be mad at your parents. They had to know a mullet mixed with a lazy eye and that weird brillo pad looking hairstyle wasn’t going to produce the next Brad Pitt, but they bumped uglies anyways because this is America goddamnit. Everyone has something to offer, and if perfect facial symmetry isn’t your thing maybe you’re good at something else. I mean, I’d probably be good at it too, but I can lay back some to let you shine. I don’t need every spotlight. It’s not good for my perfect skin anyways.

#BlueSteel

Last but not least, let’s make some predictions.

I predict we get BTD and that it moves the needle. People track that shit and try to catch a wave. We’d also get some legit news coverage from it. It wouldn’t take that much buying pressure to overwhelm those exerting selling pressure.

We’ll get good results for 700mg. They just need the time they’ve always needed, and every other company has needed, to compile it all and get it ready for the stage. Hey youngblood, I’ve seen Q3 announcements of trials unblinding where the anticipated results are in Q2 of the following year. This shit can take time. Like steak you have to allow for both proper cook and proper rest time.

We’ll get a good partnership for Nash. Which will bring about a ton of new eyes. The media doesn’t seem to want to talk about Cytodyn but if a Merck or J&J type company enters into an agreement with ya boys they’ll happily spread that message far and wide for their old buddies in big pharma.

The longhauler trial will finally start in late January and fill by early February. I’ll be starting my own longhauler treatment center ala Bruce Patterson in the meanwhile. Strike while the iron is hot. It’ll be called “Rub Some Dirt On It Treatment Center” and I’ll deliver only old man medicine. Patients will either receive dirt to rub on their wounds, a story about how kids have it too easy these days, or Iodine. Man, I remember that Iodine used to be a common thing back when I was a kid. You couldn’t so much as stub a toe without getting the Iodine. Oh no, this just in, I’m now getting reports that Dr. Yo has read this post and is already promoting Iodine to treat Longhaulers for just $900 a week.

2022 will NOT be the year that I stop saying “unggggghhhh road humps” every time I roll over a road hump while my wife is in the car.

Last but not least, if you aren’t interested in swing trading and you believe that you’ve placed your money on the right horse, don’t sweat the swings down because your bet isn’t that on any given day the price will be X. Your bet is that after approvals and partnerships and saving lives the price will be XXX. None of that (minus those lives saved on RTT or CSP so far) has occurred yet so hold those tiny horses you tiny horse having weirdos. We’re just getting started.

Okay, that’s all I have for predictions. The booth is closed. You don’t have to go home but you can’t stay here. Life is like a box of chocolates. You don’t know what you’ve got til it’s gone. If it hadn’t been for Cotton-eyed Joe I’d been married long time ago. Did we just become best friends?

#TechnicalAnalysis

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

U.S. GoldMining Eyes West Susitna Road Progress

Updated Category News Views 2

It's rare that infrastructure projects generate excitement, but U.S. GoldMining's nod to the West Susitna Access Project has the potential to shake things up in Alaska. On August 27, 2026, AIDEA greenlit a bold $25 million investment for geotechnical and engineering work, promising to bridge the Whistler Project with Southcentral Alaska's transport grid. Folks, we're...

Continue Reading
SCO at 25: China's Strategic Push for Regional Growth

Updated Category News Views 6

There's a new beat coming out of Central Asia, and it's resonating all the way from China's boardrooms to the barren landscapes of the Gobi Desert. With the Shanghai Cooperation Organization (SCO) celebrating its 25th anniversary, we're witnessing a pivot from a security-centric setup to a full-blown economic collaboration machine. The Landscape of SCO's Evolution Look,...

Continue Reading
ASUS Harnesses AI Power with ProArt RTX Spark PCs

Updated Category News Views 2

When ASUS throws its hat in the ring, you know it's going for the knockout. At IFA 2026, they're swinging for the fences with their new ProArt lineup—powered by NVIDIA RTX Spark. We're talking serious AI muscle here, up to 1 petaflop worth! What Makes This Lineup a Game Changer? The ProArt series, comprising of the P16 and P14 laptops, alongside the GR1X mini PC, is a...

Continue Reading
Arrow's Clever DIY Push with T301 & Serena Appiah

Updated Category News Views 1

Arrow's Halloween Play: Enter the "Light the Fright" Ever seen DIY weaponry double as a Halloween trick? Arrow Tool Group's stepping into spooky season with their "Light the Fright" Halloween Giveaway, bringing in DIY dynamo Serena Appiah to showcase their T301 Multi-Tacker Staple Gun. Now, this isn't just another run-of-the-mill promo. They're handing over an arsenal...

Continue Reading
Top Tax Expert Holly Paz Joins alliant's Elite Team

Updated Category News Views 3

Big Leagues in Tax: Holly Paz Joins alliant Tax is one of those fields that's not for the faint of heart. It's complex, ever-changing, and can make or break businesses. Enter Holly Paz, once at the helm of the IRS's Large Business & International Division, now bringing her vast experience to alliant. Paz is a bona fide heavyweight in tax administration, and her arrival at...

Continue Reading
Nauticus Robotics' ROV Activity Boosts Q3 Performance

Updated Category News Views 1

Nauticus Robotics Hits New Stride with ROV Deployments Some days, you're paddling like hell to stay afloat in this market. But for Nauticus Robotics, marking progress amidst turbulent waters, their recent announcement feels like catching a favorable current. Both of Nauticus’ Comanche ROV systems have been deployed for commercial projects, enhancing their third quarter...

Continue Reading
Teamsters Strike Hits Amazon's Largest U.S. Warehouse

Updated Category News Views 8

Unrest Brewing in Riverside: Amazon's Labor Showdown September 1, 2026, marks a potentially seismic shift in labor disputes within one of America's corporate titans—Amazon. Picture this: workers slinging on their boots, not for a day of hauling goods in Amazon's largest U.S. warehouse, DJT6, but for a united stand outside its gates. Who's at the helm? The Teamsters...

Continue Reading
iRobot's Roomba Max 875: The Ultimate Cleaning Machine

Updated Category News Views 2

Roomba Max 875 Combo: Setting a New Standard Alright, folks, iRobot's at it again—unleashing what they tout as their beefiest cleaner to date, the Roomba Max 875 Combo Robot. It's a name that might twist your tongue, and this technological titan's feature list is equally complex. You know the routine with these fancy gadget launches: big promises, shiny features, but...

Continue Reading
Clean Energy's Paradox: Speed vs. Emission Cuts

Updated Category News Views 4

Tackling the Two-Speed Transition It's like this: clean energy's racing ahead but dragging a stubborn mule behind. Sure, we saw solar and EVs hustle past every forecast last year, with a record-breaking $2.1 trillion in investment. But, ever notice how despite all this, emissions aren't exactly nose-diving? Global CO2's hovering like a bad cold, thanks to the unending...

Continue Reading
Pricing Strategies in Show Low: Key Insights Revealed

Updated Category News Views 4

Understanding the Unique Real Estate Landscape in Show Low When it comes to selling a home in Show Low, Arizona, price ain't just a number thrown on a sheet. It’s more like a dance—where setting the right rhythm can lead to interested home-buying partners. Real estate experts Josh Meacham and Anthony Marangon of HomeSmart Pros break down the moves in their...

Continue Reading

Top 5 Most Recently Viewed Articles

Hansei Solutions Announces New COO for Enhanced Operations

Updated Category News Views 112

Hansei Solutions Welcomes New COO Nick Rogers Hansei Solutions, known for its expertise in revenue cycle management (RCM) in the behavioral health sector, has appointed Nick Rogers as Chief Operating Officer (COO). This strategic decision aims to boost operational growth and technological advancement within the company. Nick Rogers: A Leader with Proven Expertise With...

Continue Reading
Future of Financial Planning: Expectations Revealed

Updated Category News Views 2

The Next Wave in Financial Planning So, here we are, standing at the crossroads of financial planning's future. We're seeing not only how the next generation is shaping up but also the very terms they're setting for employers. FP Transitions just dropped some revealing research on us. It's about time someone asked these young hotshots what they really want. And surprise,...

Continue Reading
Stay Informed: United Parcel Service's Upcoming Investor Actions

Updated Category News Views 56

Important Investor Information for United Parcel Service As a shareholder in United Parcel Service, Inc. (NYSE: UPS), you may want to stay abreast of recent developments that could impact your investments. It's essential to understand what steps you can take if you have been affected by company actions in the past. Understanding Your Rights as a Shareholder Have you owned...

Continue Reading
SeAH A&D Garnering Accolades for Boeing Supply Success

Updated Category News Views 6

Boeing's Nod to SeAH: A Big Win in Aerospace SeAH Aerospace & Defense just bagged one of those shiny recognitions from Boeing, the Supplier Production Partner Award. It's akin to the Oscars in aerospace supply chains, a pat on the back for doing things right. Boeing's not one to dish these out casually, so it's no garden-variety endorsement. This moves SeAH firmly into...

Continue Reading
GH Research Advances Treatment for Depression at ECNP Congress

Updated Category News Views 130

GH Research Announces Key Symposium Participation GH Research PLC (NASDAQ: GHRS), a pioneering biopharmaceutical company focused on innovative depression treatments, has been selected to present significant findings at a prominent conference. The upcoming 38th Annual European College of Neuropsychopharmacology Congress (ECNP) will take place from October 11 to 14, where...

Continue Reading